Menu Close

Johnson & Johnson (NYSE:JNJ) Shares Purchased by Baker Tilly Wealth Management LLC

view original post

Baker Tilly Wealth Management LLC boosted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 1.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,799 shares of the company’s stock after purchasing an additional 390 shares during the quarter. Johnson & Johnson comprises approximately 0.7% of Baker Tilly Wealth Management LLC’s investment portfolio, making the stock its 28th largest position. Baker Tilly Wealth Management LLC’s holdings in Johnson & Johnson were worth $6,167,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Magnolia Capital Management Ltd. boosted its holdings in Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after acquiring an additional 55 shares during the period. Howard Financial Services LTD. boosted its stake in shares of Johnson & Johnson by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after buying an additional 57 shares during the period. Capital Investment Counsel Inc boosted its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock valued at $1,334,000 after buying an additional 59 shares during the period. Kwmg LLC boosted its stake in shares of Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after buying an additional 59 shares during the period. Finally, Beaton Management Co. Inc. boosted its stake in shares of Johnson & Johnson by 0.3% in the 4th quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company’s stock valued at $3,806,000 after buying an additional 60 shares during the period. 68.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Raymond James lifted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Credit Suisse Group lifted their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Citigroup cut their target price on Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. Daiwa Capital Markets started coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company raised their target price on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $191.29.

Johnson & Johnson Trading Down 1.5 %

JNJ opened at $171.69 on Wednesday. The firm has a market cap of $451.79 billion, a price-to-earnings ratio of 23.14, a price-to-earnings-growth ratio of 3.54 and a beta of 0.63. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The business’s 50 day moving average is $176.59 and its two-hundred day moving average is $174.37. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 earnings per share. On average, research analysts predict that Johnson & Johnson will post 10.19 EPS for the current year.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Insiders have sold a total of 78,161 shares of company stock valued at $13,895,302 over the last quarter. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.